IMS Health, SDI and Source Healthcare Analytics issued the following statement regarding the U.S. Supreme Court's order granting

IMS Health, SDI and Source Healthcare Analytics issued the following statement regarding the U.S. Supreme Court's order granting certiorari in IMS v. Sorrell
"We are pleased that the Supreme Court accepted our recommendation to review the constitutionality of state laws banning the use of physician prescribing information in the truthful marketing of safe and effective medicine. We believe the justices will agree with the Court of Appeals that laws like this one violate the First Amendment right of free speech. In addition, we applaud the decision of the great majority of states and the federal government not to adopt similar restrictions, which harm patients by making it more difficult to communicate timely and often vital information about new medicine and safety updates on existing medicine."
###
For more information and materials related to this case please go to: www.imsfreespeech.org
About IMS
Operating in more than 100 countries, IMS Health is the world's leading provider of market intelligence to the pharmaceutical and healthcare industries. With more than 55 years of industry experience, IMS offers leading-edge market intelligence products and services that are integral to clients' day-to-day operations, including product and portfolio management capabilities; commercial effectiveness innovations; managed care and consumer health offerings; and consulting and services solutions that improve productivity and the delivery of quality healthcare worldwide. Additional information is available at http://www.imshealth.com
As a global leader in protecting individual patient privacy, IMS uses de-identified healthcare data to deliver critical, real-world disease and treatment insights. These insights help biotech and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders to identify unmet treatment needs and understand the effectiveness and value of pharmaceutical products in improving overall health outcomes.
About SDI
SDI is a leading healthcare market insight and analytics firm. It provides the industry's most comprehensive de-identified patient-level data to pharmaceutical, biotech, retail pharmacy, and medical device companies, enabling them to better understand the healthcare market. SDI also serves the government and the financial services, media, and consumer packaged goods industries. Founded in 1982, SDI counts the world's top 50 pharmaceutical and biotech firms as its clients. For more information, visit www.sdihealth.com
About Wolters Kluwer Pharma Solutions
Wolters Kluwer Pharma Solutions, Inc. (Bridgewater, NJ) is a leading provider of information and analytics to the pharmaceutical, biotech, and medical device industries. The company's brands include Adis, Source® and VisionCare Group. A provider of business intelligence and services, Adis publishes peer-reviewed pharmacology publications and offers the most respected drug and clinical trials databases in the pharma industry. A longstanding provider of market data and healthcare analytics, Source® offers a unique set of comprehensive patient and physician-level prescribing and usage data. VisionCare Group is a publisher of business and specialty publications and producer of conferences and e-media products. For more information, visit www.wolterskluwerpharma.com.

Contacts:
Phil Oliva
IMS Health
(203)845-5345
[email protected]
Scott Evans
SDI
(484)-567-6353
[email protected]

Robert Dekker Wolters Kluwer Health & Pharma Solutions (215) 521-8928 [email protected]

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.